AbbVie Korea

Part of AbbVie

CompanySouth Korea

AbbVie Korea develops one asset, approved (upadacitinib in Active Rheumatoid Arthritis). Mostly small molecule acting on JAK2, JAK1 and JAK3; based in South Korea.

1
Asset
Furthest stage
Approved
0
Trials
11
Signals

Pipeline

1
  • upadacitinib

    Inhibits JAK1 to suppress inflammatory cytokine signaling.

    Approved, Small molecule, JAK2, JAK1, Active Rheumatoid Arthritis, ulcerative colitis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Signals20
  • Similar companies6

Intelligence